CAR T-cell Therapy
A2B530 CAR T Therapy for Solid Cancers
This trial tests A2B530, a treatment using modified immune cells from the patient, in adults with hard-to-treat cancers like colorectal, pancreatic, and lung cancer. The treatment aims to target and kill cancer cells while protecting healthy cells.
Tyrosine Kinase Inhibitor
Pazopanib for Carcinoid Tumor
This trial is testing how well pazopanib hydrochloride works in treating patients with carcinoid tumors. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Popular Filters
Trials for Adenocarcinoma Patients
Monoclonal Antibodies
SGN-BB228 for Melanoma
This trial is testing a new drug called SGN-BB228 to see if it can help treat difficult-to-treat cancers like melanoma and other solid tumors. The study will determine the safest amount of the drug to give and check if it works in shrinking or eliminating these tumors. The goal is to find a new treatment option for patients whose cancers are not responding to current therapies.
MDM2 Inhibitor
Brigimadlin for Solid Cancers
This trial is testing a medicine called BI 907828 for adults with advanced cancer in the biliary tract, pancreas, lung, or bladder who have no other treatment options. The medicine is taken as a tablet periodically and works by blocking a protein that helps cancer cells grow.
CAR T-cell Therapy
TC-510 Cell Therapy for Cancer
This trial tests TC-510, a therapy using a patient's own modified T cells to target and attack cancer cells. It is aimed at patients with cancers that are hard to treat with standard methods. The modified T cells are designed to recognize specific proteins on cancer cells and get an extra boost to kill them.
Small Molecule Inhibitor
LY3537982 for Cancer
This trial is testing a new drug called LY3537982 in cancer patients with the KRAS G12C mutation. It targets this mutation to stop cancer cells from growing. The study includes patients who haven't responded to other treatments or cannot tolerate them. LY3537982 is a new drug targeting the KRAS G12C mutation, similar to previously approved drugs like sotorasib and adagrasib.
Trials for Pancreatic Endocrine Carcinoma Patients
Monoclonal Antibodies
SGN-BB228 for Melanoma
This trial is testing a new drug called SGN-BB228 to see if it can help treat difficult-to-treat cancers like melanoma and other solid tumors. The study will determine the safest amount of the drug to give and check if it works in shrinking or eliminating these tumors. The goal is to find a new treatment option for patients whose cancers are not responding to current therapies.
MDM2 Inhibitor
Brigimadlin for Solid Cancers
This trial is testing a medicine called BI 907828 for adults with advanced cancer in the biliary tract, pancreas, lung, or bladder who have no other treatment options. The medicine is taken as a tablet periodically and works by blocking a protein that helps cancer cells grow.
CAR T-cell Therapy
TC-510 Cell Therapy for Cancer
This trial tests TC-510, a therapy using a patient's own modified T cells to target and attack cancer cells. It is aimed at patients with cancers that are hard to treat with standard methods. The modified T cells are designed to recognize specific proteins on cancer cells and get an extra boost to kill them.
Small Molecule Inhibitor
LY3537982 for Cancer
This trial is testing a new drug called LY3537982 in cancer patients with the KRAS G12C mutation. It targets this mutation to stop cancer cells from growing. The study includes patients who haven't responded to other treatments or cannot tolerate them. LY3537982 is a new drug targeting the KRAS G12C mutation, similar to previously approved drugs like sotorasib and adagrasib.
Trials for Metastatic Patients
Monoclonal Antibodies
SGN-BB228 for Melanoma
This trial is testing a new drug called SGN-BB228 to see if it can help treat difficult-to-treat cancers like melanoma and other solid tumors. The study will determine the safest amount of the drug to give and check if it works in shrinking or eliminating these tumors. The goal is to find a new treatment option for patients whose cancers are not responding to current therapies.
MDM2 Inhibitor
Brigimadlin for Solid Cancers
This trial is testing a medicine called BI 907828 for adults with advanced cancer in the biliary tract, pancreas, lung, or bladder who have no other treatment options. The medicine is taken as a tablet periodically and works by blocking a protein that helps cancer cells grow.
CAR T-cell Therapy
TC-510 Cell Therapy for Cancer
This trial tests TC-510, a therapy using a patient's own modified T cells to target and attack cancer cells. It is aimed at patients with cancers that are hard to treat with standard methods. The modified T cells are designed to recognize specific proteins on cancer cells and get an extra boost to kill them.
Small Molecule Inhibitor
LY3537982 for Cancer
This trial is testing a new drug called LY3537982 in cancer patients with the KRAS G12C mutation. It targets this mutation to stop cancer cells from growing. The study includes patients who haven't responded to other treatments or cannot tolerate them. LY3537982 is a new drug targeting the KRAS G12C mutation, similar to previously approved drugs like sotorasib and adagrasib.
Trials for BRCA1 Positive Patients
PARP Inhibitor
Gemcitabine + Cisplatin +/- Veliparib for Pancreatic Cancer
This trial is studying veliparib in combination with gemcitabine hydrochloride and cisplatin to see how well it works compared to gemcitabine hydrochloride and cisplatin alone in treating patients with pancreatic cancer.
Alkylating agents
Chemotherapy + Stem Cell Transplant for Pancreatic Cancer
This trial is testing a new treatment for pancreatic cancer in patients with an inherited BRCA1 or BRCA2 mutation. The treatment involves a combination of drugs given through an IV, with the goal of determining if it is safe.
PARP Inhibitor
Pembrolizumab + Olaparib for Pancreatic Cancer
This trial is testing whether adding pembrolizumab to olaparib, which is the standard of care, is more effective in treating patients with metastatic pancreatic cancer who have BRCA1 or BRCA2 mutations.
Trials for BRCA2 Positive Patients
PARP Inhibitor
Gemcitabine + Cisplatin +/- Veliparib for Pancreatic Cancer
This trial is studying veliparib in combination with gemcitabine hydrochloride and cisplatin to see how well it works compared to gemcitabine hydrochloride and cisplatin alone in treating patients with pancreatic cancer.
Alkylating agents
Chemotherapy + Stem Cell Transplant for Pancreatic Cancer
This trial is testing a new treatment for pancreatic cancer in patients with an inherited BRCA1 or BRCA2 mutation. The treatment involves a combination of drugs given through an IV, with the goal of determining if it is safe.
PARP Inhibitor
Pembrolizumab + Olaparib for Pancreatic Cancer
This trial is testing whether adding pembrolizumab to olaparib, which is the standard of care, is more effective in treating patients with metastatic pancreatic cancer who have BRCA1 or BRCA2 mutations.
Phase 3 Trials
Anti-metabolites
Chemotherapy for Pancreatic Cancer
This trial is studying gemcitabine hydrochloride given with or without erlotinib hydrochloride, followed by the same chemotherapy regimen with or without radiation therapy and capecitabine or fluorouracil, to see how well it works in treating patients with pancreatic cancer that has been removed by surgery.
Anti-metabolites
Intra-arterial vs. IV Chemotherapy for Pancreatic Cancer
This trial tests different ways to treat advanced pancreatic cancer that can't be removed by surgery. It uses a combination of chemotherapy drugs and radiation, then compares direct artery chemotherapy to other treatments.
Tyrosine Kinase Inhibitor
Cabozantinib for Pancreatic Neuroendocrine Tumors
This trial compares cabozantinib to placebo in treating neuroendocrine or carcinoid tumors. Cabozantinib is a chemotherapy drug that targets specific tyrosine kinase receptors, which when blocked, may slow tumor growth.
Chemotherapy
Multiple Regimens for Metastatic Pancreatic Cancer
This trial is designed to compare multiple investigational regimens against standard of care in metastatic pancreatic cancer patients, in order to determine which, if any, patients benefit from each investigational arm. Secondary objectives include determining short- and long-term safety signals of each investigational arm, as well as progression-free survival and response rates.
Trials With No Placebo
Monoclonal Antibodies
SGN-BB228 for Melanoma
This trial is testing a new drug called SGN-BB228 to see if it can help treat difficult-to-treat cancers like melanoma and other solid tumors. The study will determine the safest amount of the drug to give and check if it works in shrinking or eliminating these tumors. The goal is to find a new treatment option for patients whose cancers are not responding to current therapies.
MDM2 Inhibitor
Brigimadlin for Solid Cancers
This trial is testing a medicine called BI 907828 for adults with advanced cancer in the biliary tract, pancreas, lung, or bladder who have no other treatment options. The medicine is taken as a tablet periodically and works by blocking a protein that helps cancer cells grow.
CAR T-cell Therapy
TC-510 Cell Therapy for Cancer
This trial tests TC-510, a therapy using a patient's own modified T cells to target and attack cancer cells. It is aimed at patients with cancers that are hard to treat with standard methods. The modified T cells are designed to recognize specific proteins on cancer cells and get an extra boost to kill them.
Small Molecule Inhibitor
LY3537982 for Cancer
This trial is testing a new drug called LY3537982 in cancer patients with the KRAS G12C mutation. It targets this mutation to stop cancer cells from growing. The study includes patients who haven't responded to other treatments or cannot tolerate them. LY3537982 is a new drug targeting the KRAS G12C mutation, similar to previously approved drugs like sotorasib and adagrasib.
View More Related Trials
Frequently Asked Questions
Introduction to pancreatic cancer
What are the top hospitals conducting pancreatic cancer research?
Pancreatic cancer, a devastating and often challenging disease to treat, has led some hospitals to the forefront of groundbreaking clinical trials. At Memorial Sloan Kettering Cancer Center in New york City, nine active pancreatic cancer trials are currently underway, building upon their impressive portfolio of 44 completed trials since their first recorded investigation in 2006. Similarly, Massachusetts General Hospital in Boston is making significant strides with five ongoing pancreatic cancer trials and an extensive history of 49 previous studies dating back to their inaugural trial in 1998.
Boston's Dana Farber Cancer Institute also contributes to this vital research with five active pancreatic cancer trials and a commendable track record of 27 past investigations since initiating their first trial in collaboration with Memorial Sloan Kettering in 2006. While located away from the major medical hubs, Katmai Oncology Group based in Anchorage has emerged as a key player too. This institute is conducting five current clinical tests for pancreatic cancer while having accomplished twelve earlier groundbreaking experiments since recording its pioneering trial back in 2009.
In Palo Alto, California resides another institution dedicated to advancing knowledge about this challenging form of cancer – the Palo Alto Medical Foundation Health Care. Currently engaged in five active pancreatic cancer trials and contributing significantly towards understanding the disease through eight previously conducted investigations; theirs can be traced back only twelve years ago to when they initiated their first recorded trial on this subject matter during 2009.
These leading hospitals signify hope against all odds by investing time, resources, and expertise into finding novel solutions for patients battling pancreatic cancer worldwide. Their unwavering commitment paves the way for progress toward improved treatments and outcomes that could one day change countless lives affected by this relentless disease
Which are the best cities for pancreatic cancer clinical trials?
When it comes to pancreatic cancer clinical trials, several cities are leading the way in research and development. New york, with its 27 active trials, focuses on treatments such as LY3537982, Piperacillin-tazobactam, and more. Anchorage follows closely behind with 26 ongoing studies that explore options like Fluorouracil and Subprotocol C2 (MET exon 14 deletion/mutation). Los Angeles also stands out with 23 active trials examining therapies like Pazopanib Hydrochloride and Chemotherapy. These cities offer individuals battling pancreatic cancer access to cutting-edge clinical trials that pave the way for advancements in care and hope for better outcomes.
Which are the top treatments for pancreatic cancer being explored in clinical trials?
Pancreatic cancer clinical trials are delving into various treatment options, with some standout contenders taking the lead. Gemcitabine, a well-established player in the field since its listing in 1998, remains at the forefront with two active and an impressive 248 all-time pancreatic cancer trials. Another noteworthy contender is pharmacological studies specifically targeting pancreatic cancer, currently underway in two active trials amidst a total of 15 past investigations since being introduced in 2007. Similarly, gemcitabine hydrochloride has shown promise with two ongoing clinical trials and a history of participation in 21 previous pancreatic cancer studies starting from 2003. Lastly, chemotherapy continues to be explored as an important approach for fighting this challenging disease through two active trials and past involvement in fourteen clinical investigations since its first listing back in 2009. As researchers continue their relentless pursuit for effective treatments against pancreatic cancer, these top contenders offer hope on the horizon.
What are the most recent clinical trials for pancreatic cancer?
Promising advancements in the fight against pancreatic cancer have emerged through recent clinical trials. Noteworthy among them is A2530, a trial that explores new treatment options for this challenging disease. Additionally, SGN-BB228 has shown potential as a therapeutic approach to combat pancreatic cancer. Another avenue of research involves the use of brigimadlin (BI 907828) as an experimental treatment option in Phase 2 trials. Furthermore, PT199 and TC-510 are being evaluated in Phase 1 and Phase 2 trials respectively, offering hope for improved outcomes and increased survival rates for patients battling pancreatic cancer. These ongoing studies mark significant progress toward finding effective treatments to combat this formidable illness.
What pancreatic cancer clinical trials were recently completed?
In recent years, numerous clinical trials have been completed in the quest to improve treatments for pancreatic cancer. Noteworthy among them are a trial investigating Cisplatin sponsored by CanBas Co. Ltd., which concluded in December 2021; a trial testing Dapagliflozin led by Washington University School of Medicine, completed in February 2021; and a Plerixafor study supported by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, finalized in November 2020. These trials highlight the ongoing efforts of researchers to advance our understanding and treatment options for this challenging disease.